The Pharma Data

JANUARY 25, 2021

a biotechnology company developing cell and gene therapy treatments for patients suffering from vascular disease, today announced that it raised up to $5.5M that will lead clinical testing of a novel gene therapy for a serious vascular disease in Europe. The company is a 2019 spin-out of the University of Miami co-founded by Robert L.

Therapies 52

Therapies Disease Licensing Licensing 52

The Pharma Data

AUGUST 17, 2020

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. About Bristol Myers Squibb. About Dragonfly. Dragonfly has a deep pipeline of wholly owned programs developed using its platform.

Licensing 52

Licensing Licensing Production Clinical Trials 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

The Pharma Data

DECEMBER 16, 2020

NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., The agreement leverages Otsuka’s well-recognized expertise in rare kidney diseases to underscore Aurinia’s commitment to expanding global access to voclosporin for the treatment of LN.

Licensing 52

Licensing Licensing Pharmaceuticals Disease 52

Drug Discovery World

MARCH 7, 2023

She has over 15 years’ experience in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Here at FAB our proprietary approach aims to overcome this fundamental challenge to human health as we work to discover and develop new drugs for age-associated diseases.”

International 246

International Science Pharmaceuticals DNA 246

The Pharma Data

MAY 4, 2021

Lilly is offering donations of baricitinib to the Indian government through Direct Relief while simultaneously working with local Indian pharmaceutical companies to execute royalty-free voluntary licensing agreements to accelerate the manufacturing and distribution of the medicine in India during the pandemic.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China. February 2019.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

NOVEMBER 23, 2020

NYSE American: SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need. . ROCKVILLE, Md. , 24, 2020 /PRNewswire/ — Synthetic Biologics, Inc. Synthetic Biologics, Inc.

Compliance 52

Compliance Licensing Licensing Clinical Trials 52

The Pharma Data

OCTOBER 29, 2020

If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer’s disease and to meaningfully change the course of Alzheimer’s disease. If approved, aducanumab would become the first therapy to reduce the clinical decline in patients with Alzheimer’s disease. CAMBRIDGE, Mass.

Marketing 40

Marketing Disease Clinical Trials Treatment 40

The Pharma Data

JANUARY 17, 2021

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. Launched in 2019, the company raised $700 million in June 2020 in its initial financing. Harr was also a director for Loxo Oncology.

Marketing 52

Marketing Engineering Therapies Disease 52

The Pharma Data

MARCH 15, 2022

The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc.,

FDA 52

FDA Licensing Licensing Trials 52

Drug Discovery World

NOVEMBER 29, 2022

The new Clinical Pharmacology degree was launched in 2019 by Professors Emma Baker and Iain Greenwood and aims to take a holistic view of the development of drugs and create graduates that will stand out in the job market. These are: Fundamentals of science: Understanding how the body works and what goes wrong in disease.

Clinical Pharmacology 130

Clinical Pharmacology Clinical Trials Drugs Drug Development 130

New Drug Approvals

AUGUST 21, 2023

4] [5] History Palovarotene is a retinoic acid receptor gamma (RARγ) agonist licensed to Clementia Pharmaceuticals from Roche Pharmaceuticals. At Roche, palovarotene was evaluated in more than 800 individuals including healthy volunteers and patients with chronic obstructive pulmonary disease (COPD). [7] Retrieved 15 December 2019.

FDA 52

FDA Clinical Trials Pharmaceuticals Treatment 52

The Pharma Data

NOVEMBER 29, 2020

2019, 62 , 445?447. HK) is a globally, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. On October 28, 2019 , Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK. About Ascentage Pharma.

Licensing 40

Licensing Licensing Small Molecule Clinical Trials 40

The Pharma Data

JANUARY 17, 2021

plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields. SEOUL, South Korea , Jan. Hanmi Pharmaceutical Co.,

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

JANUARY 14, 2021

“Buprenorphine is the most important medication in our arsenal for treating opioid use disorder, which is currently one of the most lethal diseases for Americans.” As a result, some clinicians are hesitant to pursue this DEA license or even engage in treatment of patients with OUD.

Treatment 52

Treatment Licensing Licensing Hospitals 52

Drug Discovery World

MARCH 29, 2023

UMNs have been defined in the context of the draft as diseases where there’s a lack of good treatments, and which have a high burden 3. For rare disease drugs, a variable RDP period of five, nine, or ten years, depending on the novelty of the drug.

Clinical Trials 130

Clinical Trials Biosimilars Pharma Companies Production 130

The Pharma Data

JUNE 24, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. Source link:[link].

Vaccine 52

Vaccine Immune Response FDA Licensing 52

Drug Discovery World

MAY 6, 2024

Amsterdam: The centre of European life sciences As a result of the UK withdrawing from the EU, in 2019 the EMA headquarters was moved from London to Amsterdam. The company is now investigating a promising gene therapy for Huntingdon’s disease in a Phase I/II trial, with patients already showing signs of preserved neurological function.

Drugs 147

Drugs Science Molecular Biology Clinical Trials 147

The Pharma Data

JANUARY 25, 2021

26, 2021 /PRNewswire/ — Asieris Pharmaceuticals announced today that the company has entered into a license agreement with Photocure ASA (Photocure, PHO: OSE) to exclusively register and commercialize Hexvix® in Mainland China and Taiwan. SHANGHAI , Jan. Founder and CEO of Asieris. ” About Photocure ASA. About Asieris.

Licensing 40

Licensing Licensing Clinical Development Pharmaceutical Companies 40

The Pharma Data

JANUARY 5, 2021

Ribometrix’s technology platform focuses on identify 3D “motifs” in RNA molecules so it can then design small molecule drugs that bind to these motifs to treat diseases. So therapeutics that focus on RNA are designed to stop the DNA from coding for disease-causing proteins.

RNA 52

RNA Small Molecule DNA Licensing 52

The Pharma Data

NOVEMBER 8, 2020

The Series B financing will be mainly used to conduct global clinical trials, research and development, and product in-licensing activities. The development of drugs for immunology-related diseases is still a ‘blue ocean’ in China. To date, Inmagene has raised over $40 million financing. View original content: [link].

Clinical Trials 40

Clinical Trials Licensing Licensing Trials 40

The Pharma Data

APRIL 1, 2021

Vaccine was 100% effective in preventing severe disease as defined by the U.S. Centers for Disease Control and Prevention and 95.3% effective in preventing severe disease as defined by the U.S. The vaccine was 100% effective against severe disease as defined by the U.S. Food and Drug Administration.

Vaccine 52

Vaccine FDA Licensing Licensing 52

The Pharma Data

FEBRUARY 25, 2022

Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). The root cause of many immunological diseases is immuno-inflammation, which requires specifically designed agents.

Biosimilars 52

Biosimilars FDA FDA Approval Small Molecule 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. This press release features multimedia. In the U.S.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

MARCH 16, 2021

Head of Department CNS Diseases Research at Boehringer Ingelheim. “By While peripherally acting COMT inhibitors are currently used as an adjunctive therapy in the treatment of neurological conditions, including Parkinson’s disease, this new collaboration is investigating centrally acting COMT inhibitors in neuropsychiatric disorders.

Licensing 52

Licensing Licensing Research Laboratories Pharmaceutical Companies 52

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. There is an incredible unmet need in some diseases that can only be addressed through cell and gene therapies.”. Photo courtesy of Bayer.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

New Drug Approvals

SEPTEMBER 10, 2024

2019/0160068 (the teachings of which are incorporated herein by reference), to produce CTP-543 and/or its phosphate salt. -(cyclopentyl-2,2,3,3,4,4,5,5-d8)-4-(7h-pyrrolo(2,3-d)pyrimidin-4-yl)-, (.beta.r)-D8-ruxolitinib 1] It is a Janus kinase inhibitor selective for JAK1 and JAK2. [2] 9,249,149 and US Patent Pub.

FDA Approval 52

FDA Approval FDA Treatment Clinical Trials 52

The Pharma Data

OCTOBER 20, 2020

We look forward to successful commercialization and licensing of TLC’s programs across the globe under Mr. Bliss’s leadership, as well as to creating benefit and bringing value for all of TLC’s stakeholders.”. TLC is consistently ranked top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.

Licensing 40

Licensing Licensing Pharmaceutical Companies Pharmaceuticals 40

New Drug Approvals

OCTOBER 24, 2023

1 Therefore, S1P receptor modulators like etrasimod were investigated in treating immune-mediated diseases like ulcerative colitis where a high level of inflammatory T cells is present in the gastrointestinal tract, thus causing diffuse mucosal inflammation. June 2019). “Velsipity (etrasimod) tablets, for oral use” (PDF).

FDA 57

FDA FDA Approval International Pharmacokinetics 57

The Pharma Data

NOVEMBER 11, 2020

. Received Rare Pediatric Disease and Fast Track Designations for INZ-701 for the treatment of ENPP1 deficiency. ENPP1 deficiency is a systemic, progressive and continuous disease occurring over the course of a patient’s lifetime, starting as early as fetal development and spanning into adulthood. BOSTON, Nov.

Clinical Trials 40

Clinical Trials Trials Disease FDA 40

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity. Senior Vice President and Global Head of Cardiometabolic Diseases Research, Boehringer Ingelheim. population will have obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

The Pharma Data

OCTOBER 26, 2020

The National Institute of Allergy and Infectious Diseases (NIAID), the study sponsor, could not verify the safety issue, but their analysis also indicated there was little likelihood the antibody would help the hospitalized patients. The approval marks the first drug approved by the U.S. Organizational Actions/Announcements .

Vaccine 52

Vaccine FDA Approval FDA Clinical Trials 52

The Pharma Data

MARCH 26, 2021

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. Food and Drug Administration (FDA), but has been authorized for emergency use by FDA under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older.

Vaccine 52

Vaccine Doctors Pharmacy FDA 52

The Pharma Data

MARCH 2, 2021

This decision was based on the totality of scientific evidence, including data from the Phase 3 ENSEMBLE study that demonstrated the vaccine was 85 percent effective in preventing severe disease across all regions studied, and showed protection against COVID-19 related hospitalization and death, beginning 28 days after vaccination.

Vaccine 52

Vaccine Clinical Trials FDA Hospitals 52

The Pharma Data

JANUARY 24, 2021

Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. billion during 2019-2023 (Technavio 2019).

FDA 52

FDA Drugs Clinical Development Pharmaceutical Companies 52

The Pharma Data

JULY 23, 2021

Vaccines have been and will remain critical to protecting lives against this devastating disease,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. “As a long-term partner to the U.S. These additional doses will help the U.S.

Vaccine 52

Vaccine Government Immune Response FDA 52